{
  "prompt": {
    "guidelineId": "mp003-antenatal-screening-sickle-cell-and-thalassaemia-pdf",
    "fieldsProcessed": [
      "humanFriendlyName",
      "organisation",
      "yearProduced",
      "summary"
    ],
    "enhancedFields": 4,
    "contentLength": 3596
  },
  "response": "{\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"**Antenatal Screening for Sickle Cell and Thalassaemia**\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"NHS\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"2001\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Antenatal Screening for Sickle Cell and Thalassaemia Guidelines:** - **Screening Offer**: Offer to all pregnant women, ideally before 10 weeks. Couples aware of carrier status should be referred for further assessment. - **Process**: Samples taken at booking, sent to lab within one working day. Results typically available within 3 days (longer for rare disorders). - **Results Categories**: Non-carrier, inconclusive, clinically significant disorder, or genetic carrier. - **Father’s Sample**: Required if indicated; results determine risk (e.g., if both parents are carriers, 1 in 4 chance of affected baby). - **Declined Screening**: Document reason; option to screen later via community midwife. - **Follow-Up**: Failsafe check within 10 days to ensure results are acted upon. At-risk couples referred for counseling and prenatal diagnosis. - **Postnatal Testing**: Available for babies of high-risk couples who declined prenatal testing. - **Patient Information**: Provide written/verbal details at booking. NHS programme addresses sickle cell and thalassaemia, autosomal recessive conditions affecting hemoglobin. - **Support**: Refer carrier women to specialists; contact designated leads or external resources for further assistance\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "endpoint": "enhanceGuidelineMetadata",
  "timestamp": "2025-06-18T22-31-46",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"guidelineId\": \"mp003-antenatal-screening-sickle-cell-and-thalassaemia-pdf\",\n  \"fieldsProcessed\": [\n    \"humanFriendlyName\",\n    \"organisation\",\n    \"yearProduced\",\n    \"summary\"\n  ],\n  \"enhancedFields\": 4,\n  \"contentLength\": 3596\n}\n\nA: {\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"**Antenatal Screening for Sickle Cell and Thalassaemia**\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"NHS\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"2001\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Antenatal Screening for Sickle Cell and Thalassaemia Guidelines:** - **Screening Offer**: Offer to all pregnant women, ideally before 10 weeks. Couples aware of carrier status should be referred for further assessment. - **Process**: Samples taken at booking, sent to lab within one working day. Results typically available within 3 days (longer for rare disorders). - **Results Categories**: Non-carrier, inconclusive, clinically significant disorder, or genetic carrier. - **Father’s Sample**: Required if indicated; results determine risk (e.g., if both parents are carriers, 1 in 4 chance of affected baby). - **Declined Screening**: Document reason; option to screen later via community midwife. - **Follow-Up**: Failsafe check within 10 days to ensure results are acted upon. At-risk couples referred for counseling and prenatal diagnosis. - **Postnatal Testing**: Available for babies of high-risk couples who declined prenatal testing. - **Patient Information**: Provide written/verbal details at booking. NHS programme addresses sickle cell and thalassaemia, autosomal recessive conditions affecting hemoglobin. - **Support**: Refer carrier women to specialists; contact designated leads or external resources for further assistance\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": null
}